Why Biogen Stock Slumped Last Year

Biotech heavyweight Biogen (NASDAQ: BIIB) failed to follow the broader industry higher last year. Despite biotech stocks at large posting market-beating gains in 2019, Biogen's shares actually lost 1.4% of their value last year, according to data from S&P Global Market Intelligence. 

Biogen's stock lost ground for three key reasons in 2019:

Image source: Getty Images.

Continue reading

Source Fool.com